A groundbreaking clinical trial has revealed that an experimental anti-amyloid drug may significantly reduce the risk of developing Alzheimer’s-related dementia in individuals genetically predisposed to the disease. The study, led by the Knight Family Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU) at Washington University School of Medicine in St. Louis, marks a major step forward in the prevention of Alzheimer’s symptoms before they begin.
For the first time in a clinical setting, researchers have found that removing amyloid plaques from the brain years before symptoms emerge can delay the onset of Alzheimer’s dementia. These findings open new doors for preventive treatments and provide hope that delaying the disease for decades—or even preventing it altogether—may be possible.
Contents
A Closer Look at the Study
The international clinical trial involved 73 participants, all of whom carried rare genetic mutations that cause an overproduction of amyloid in the brain. This buildup all but guarantees that these individuals will develop Alzheimer’s disease in middle age. Among the participants, 22 individuals who received the drug the longest—an average of eight years—saw their risk of developing symptoms cut in half.
Dr. Randall J. Bateman, the lead researcher and professor of neurology at Washington University, emphasized the significance of these results. “Everyone in this study was destined to develop Alzheimer’s disease, yet some of them haven’t yet,” he stated. “We don’t yet know how long they will remain symptom-free—maybe a few years or maybe decades.”
The Role of Amyloid in Alzheimer’s Disease
Alzheimer’s disease has long been associated with amyloid plaques—sticky protein clumps that accumulate in the brain and are thought to contribute to cognitive decline. The amyloid hypothesis suggests that blocking the formation of these plaques or removing them early enough could stop the disease before symptoms arise.
This study is the first to provide clinical trial evidence supporting that theory. Researchers focused on whether an anti-amyloid drug could prevent the onset of dementia rather than just slow it down once symptoms appear.
A Decade-Long Investigation
The participants originally enrolled in the Knight Family DIAN-TU-001 study, the first Alzheimer’s prevention trial in the world. Launched in 2012, it aimed to evaluate whether anti-amyloid drugs could act as preventive therapies.
At the conclusion of the original trial in 2020, researchers found that gantenerumab, an anti-amyloid drug developed by Roche and Genentech, reduced amyloid levels in the brain and improved some measures of Alzheimer’s-related proteins. However, cognitive benefits were not immediately observed, as many of the participants had not yet reached the stage where symptoms would be expected.
To further explore gantenerumab’s long-term effects, the study leaders initiated an open-label extension, allowing all participants with high-risk genetic mutations to continue receiving the drug, regardless of their original trial group.
Key Findings and Implications
The most significant discovery was that in the subgroup of participants who received the drug for eight years, the risk of developing Alzheimer’s symptoms was reduced by approximately 50%. This calculation factored in not only how many people developed symptoms but also the timing of their symptom onset compared to their expected age.
For participants who only received gantenerumab for two to three years in the extension study, no clear cognitive benefits were observed yet. This suggests that longer treatment durations may be necessary for true prevention.
